Interstitial lung disease in systemic sclerosis: current and future treatment

Giuliana Guggino, Giovanni Triolo, Francesco Ciccia, Vasiliki Liakouli, Giuliana Guggino, Giovanni Triolo, Francesco Carubbi, Paola Di Benedetto, Piero Ruscitti, Onorina Berardicurti, Salvatore Di Bartolomeo, Francesco Ciccia, Roberto Giacomelli, Paola Cipriani

Risultato della ricerca: Articlepeer review

42 Citazioni (Scopus)


Systemic sclerosis (SSc) has the highest fatality rate among connective tissue diseases and is characterized by vascular damage, inflammation and fibrosis of the skin and various internal organs. Interstitial lung disease (ILD) frequently complicates SSc and can be a debilitating disorder with a poor prognosis. ILD is the most frequent cause of death in SSc, and the management of SScâILD patients is a great challenge. Early detection of pulmonary involvement based on a recent decline of lung function tests and on the extent of lung involvement at high-resolution computed tomography is critical for the best management of these patients. This article summarizes classification, pathogenesis, diagnosis, prognosis, survival and finally current and future treatment options in SScâILD.
Lingua originaleEnglish
pagine (da-a)853-863
Numero di pagine11
RivistaRheumatology International
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2723???
  • ???subjectarea.asjc.2700.2745???
  • ???subjectarea.asjc.2400.2403???


Entra nei temi di ricerca di 'Interstitial lung disease in systemic sclerosis: current and future treatment'. Insieme formano una fingerprint unica.

Cita questo